Compare Enveric Biosciences Inc (ENVB) vs VanEck Junior Gold Miners (GDXJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs VanEck Junior Gold Miners — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while VanEck Junior Gold Miners trades at $113.5 (market cap $8.22B). The key difference: VanEck Junior Gold Miners is far larger — about 1208.8× Enveric Biosciences Inc's market cap, and VanEck Junior Gold Miners is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and VanEck Junior Gold Miners for 41 Days on average.
| ENVB | GDXJ | |
|---|---|---|
Market Cap | $6.80M | $8.22B |
Volume | 64,867 | 3,212,198 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $10.80 | $156.19 |
52-Week Low | $1.27 | $87.56 |
Typical Hold Time | 14 Days | 41 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
GDXJ, the VanEck Junior Gold Miners ETF, is trading at $109.14, down 3.88% on the day, reflecting a bearish technical signal with selling pressure across moving averages and oscillators. Recent news highlights multiple junior gold mining companies being added to the ETF's index, potentially increasing its diversification and appeal. The ETF's current price is near key support levels, with the overall market sentiment influenced by gold price volatility and sector-specific developments.
The outlook for GDXJ is cautious due to bearish technical indicators and sector volatility, though inclusion of new companies may enhance long-term growth potential. Key risks include gold price fluctuations, mining operational risks, and broader market sentiment shifts. Investment opportunity lies in potential gold price appreciation and ETF rebalancing benefits, but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →
